These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1444095)

  • 21. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
    Loven JO; Brøndbo K; Ganes T
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Indications for botulinum toxin in laryngectomy].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E; Cohen M
    Rev Laryngol Otol Rhinol (Bord); 1993; 114(4):281-7. PubMed ID: 8029549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologic assessment of botulinum toxin effects in the rat larynx.
    Inagi K; Connor NP; Ford CN; Schultz E; Rodriquez AA; Bless DM; Pasic T; Heisey DM
    Laryngoscope; 1998 Jul; 108(7):1048-54. PubMed ID: 9665255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spasmodic dysphonia and laryngeal botulinum toxin injection.
    Smith ME
    West J Med; 1993 Jul; 159(1):74. PubMed ID: 8351914
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia.
    Hillel AD; Maronian NC; Waugh PF; Robinson L; Klotz DA
    Ann Otol Rhinol Laryngol; 2004 May; 113(5):341-8. PubMed ID: 15174759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histology of nerves and muscles in adductor spasmodic dysphonia.
    Chhetri DK; Blumin JH; Vinters HV; Berke GS
    Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):334-41. PubMed ID: 12731628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin for relief of bilateral abductor paralysis of the larynx: histologic study in an animal model.
    Cohen SR; Thompson JW; Camilon FS
    Ann Otol Rhinol Laryngol; 1989 Mar; 98(3):213-6. PubMed ID: 2923396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral thyroarytenoid denervation: a new treatment for laryngeal hyperadduction disorders studied in the canine.
    Sercarz JA; Berke GS; Ming Y; Rothschiller J; Graves MC
    Otolaryngol Head Neck Surg; 1992 Nov; 107(5):657-68. PubMed ID: 1437204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection.
    Rodriquez AA; Ford CN; Bless DM; Harmon RL
    Electromyogr Clin Neurophysiol; 1994; 34(7):403-7. PubMed ID: 7859668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
    Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
    J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.
    Grillone GA; Blitzer A; Brin MF; Annino DJ; Saint-Hilaire MH
    Laryngoscope; 1994 Jan; 104(1 Pt 1):30-2. PubMed ID: 8295454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adductor muscle activity abnormalities in abductor spasmodic dysphonia.
    Cyrus CB; Bielamowicz S; Evans FJ; Ludlow CL
    Otolaryngol Head Neck Surg; 2001 Jan; 124(1):23-30. PubMed ID: 11228447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
    Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
    Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
    Zwirner P; Murry T; Swenson M; Woodson GE
    Laryngoscope; 1992 Apr; 102(4):400-6. PubMed ID: 1556889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
    Young N; Blitzer A
    Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.